Related references
Note: Only part of the references are listed.Characteristics of SARS-CoV-2 and COVID-19
Ben Hu et al.
NATURE REVIEWS MICROBIOLOGY (2021)
A Hepatitis B Virus-Derived Peptide Exerts an Anticancer Effect via TNF/iNOS-producing Dendritic Cells in Tumor-Bearing Mouse Model
Soo-Bin Yang et al.
CANCERS (2021)
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro
Manli Wang et al.
CELL RESEARCH (2020)
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Chaolin Huang et al.
LANCET (2020)
Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19
Daniel Blanco-Melo et al.
CELL (2020)
Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure
Evangelos J. Giamarellos-Bourboulis et al.
CELL HOST & MICROBE (2020)
Type I and Type III Interferons - Induction, Signaling, Evasion, and Application to Combat COVID-19
Annsea Park et al.
CELL HOST & MICROBE (2020)
The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China
Wen Zhang et al.
CLINICAL IMMUNOLOGY (2020)
A Review of SARS-CoV-2 and the Ongoing Clinical Trials
Yung-Fang Tu et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Type I IFN immunoprofiling in COVID-19 patients
Sophie Trouillet-Assant et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2020)
Clinical and immunological features of severe and moderate coronavirus disease 2019
Guang Chen et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial
Ivan Fan-Ngai Hung et al.
LANCET (2020)
A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19
B. Cao et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
A Randomized Clinical Trial of the Efficacy and Safety of Interferon β-1a in Treatment of Severe COVID-19
Effat Davoudi-Monfared et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
Are we fully exploiting type I Interferons in today's fight against COVID-19 pandemic?
Eleonora Arico et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2020)
Non-steroidal anti-inflammatory drugs, prostaglandins, and COVID-19
Calum T. Robb et al.
BRITISH JOURNAL OF PHARMACOLOGY (2020)
Retrospective Multicenter Cohort Study Shows Early Interferon Therapy Is Associated with Favorable Clinical Responses in COVID-19 Patients
Nan Wang et al.
CELL HOST & MICROBE (2020)
Cytokine Storm in COVID-19: The Current Evidence and Treatment Strategies
Yujun Tang et al.
FRONTIERS IN IMMUNOLOGY (2020)
Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2
Markus Hoffmann et al.
NATURE (2020)
Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion
David Simon et al.
NATURE COMMUNICATIONS (2020)
Interplay between SARS-CoV-2 and the type I interferon response
Margarida Sa Ribero et al.
PLOS PATHOGENS (2020)
Type I Interferon Susceptibility Distinguishes SARS-CoV-2 from SARS-CoV
Kumari G. Lokugamage et al.
JOURNAL OF VIROLOGY (2020)
Interferons and viruses induce a novel truncated ACE2 isoform and not the full-length SARS-CoV-2 receptor
Olusegun O. Onabajo et al.
NATURE GENETICS (2020)
Inborn errors of type I IFN immunity in patients with life-threatening COVID-19
Qian Zhang et al.
SCIENCE (2020)
Autoantibodies against type I IFNs in patients with life-threatening COVID-19
Paul Bastard et al.
SCIENCE (2020)
Interferon β-1b in treatment of severe COVID-19: A randomized clinical trial
Hamid Rahmani et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2020)
Shared and Distinct Functions of Type I and Type III Interferons
Helen M. Lazear et al.
IMMUNITY (2019)
Decoding type I and III interferon signalling during viral infection
Emily Mesev et al.
NATURE MICROBIOLOGY (2019)
Origin and evolution of pathogenic coronaviruses
Jie Cui et al.
NATURE REVIEWS MICROBIOLOGY (2019)
Familial Mediterranean Fever and Multiple Sclerosis Successfully Treated With Interferon Beta-1a: A Case Report
Bilgin Ozturk
ARCHIVES OF RHEUMATOLOGY (2019)
HBV polymerase-derived peptide exerts an anti-HIV-1 effect by inhibiting the acetylation of viral integrase
Hong Kim et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2018)
Interferon β for Multiple Sclerosis
Dejan Jakimovski et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2018)
Type I interferons in viral control and immune regulation
John R. Teijaro
CURRENT OPINION IN VIROLOGY (2016)
Differential effects of IFN-β on IL-12, IL-23, and IL-10 expression in TLR-stimulated dendritic cells
Jui-Hung Yen et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2015)
Hepatitis B virus preS1 deletion is related to viral replication increase and disease progression
Seoung-Ae Lee et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2015)
Naturally Occurring Mutations in Large Surface Genes Related to Occult Infection of Hepatitis B Virus Genotype C
Hong Kim et al.
PLOS ONE (2013)
Type I Interferon Inhibits Interleukin-1 Production and Inflammasome Activation
Greta Guarda et al.
IMMUNITY (2011)
IFI16 Protein Mediates the Anti-inflammatory Actions of the Type-I Interferons through Suppression of Activation of Caspase-1 by Inflammasomes
Sudhakar Veeranki et al.
PLOS ONE (2011)
The prevalence of hepatitis B virus preS deletions occurring naturally in Korean patients infected chronically with genotype C
Ho-Suk Mun et al.
JOURNAL OF MEDICAL VIROLOGY (2008)
Molecular mechanisms of the anti-inflammatory functions of interferons
Pavel Kovarik et al.
IMMUNOBIOLOGY (2007)
Anti-inflammatory properties of Type I interferons
Alfons Billiau
ANTIVIRAL RESEARCH (2006)
Share Paper
